Yahoo
HKSE - Delayed Quote HKD

Clover Biopharmaceuticals, Ltd. (2197.HK)

1.250 -0.040 (-3.10%)
At close: October 30 at 4:08:06 PM GMT+8
Chart Range Bar
Loading chart for 2197.HK
  • Previous Close 1.290
  • Open 1.270
  • Bid 1.245 x --
  • Ask 1.250 x --
  • Day's Range 1.245 - 1.295
  • 52 Week Range 1.110 - 3.200
  • Volume 2,259,000
  • Avg. Volume 3,998,673
  • Market Cap (intraday) 1.623B
  • Beta (5Y Monthly) 2.58
  • PE Ratio (TTM) 1.69
  • EPS (TTM) 0.740
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China and internationally. The company's product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza; and SCB-219M, a thrombocytopenia receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia. It is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, the company sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.

www.cloverbiopharma.com

257

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2197.HK
46.58%
HANG SENG INDEX (^HSI)
9.11%

1-Year Return

2197.HK
40.19%
HANG SENG INDEX (^HSI)
11.37%

3-Year Return

2197.HK
89.39%
HANG SENG INDEX (^HSI)
33.83%

5-Year Return

2197.HK
90.66%
HANG SENG INDEX (^HSI)
8.21%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    197,942.80%

  • Return on Assets (ttm)

    -44.48%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    430k

  • Net Income Avi to Common (ttm)

    851.15M

  • Diluted EPS (ttm)

    0.740

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    101.55M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: